TScan Therapeutics, Inc. (TCRX)
NGM · Healthcare · Biotechnology
Closing price as of 2026-09-11 · Source: TEK2day Finance
Key Metrics
About TScan Therapeutics, Inc.
TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product is TSC-101, for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell transplantation (HCT), which is in Phase I clinical trial, as well as eliminates residual disease and promotes donor chimerism. It also develops TSC-102-A01 and TSC-102-A03, which are allogeneic and donor-derived TCR-T therapy candidates targeting epitopes. In addition, the company develops TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. It has a research collaboration and license agreement with Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
Quarterly Financials
| Metric | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|
| Revenue | 2.5M | 2.6M | 982K | 1.1M |
| Operating Income | (37.1M) | (23.9M) | (29.1M) | (30.5M) |
| Net Income | (35.7M) | (23.0M) | (28.7M) | (30.4M) |
| Diluted EPS | $-0.28 | $-0.18 | $-0.22 | $-0.23 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 13.5M | 21.0M | 2.8M | 10.3M |
| Operating Income | (66.6M) | (93.5M) | (134.8M) | (135.8M) |
| Net Income | (66.2M) | (89.2M) | (127.5M) | (129.8M) |
| Diluted EPS | $-2.75 | $-1.36 | $-1.14 | $-1.00 |